[1] Kumamoto, H. K. Ooya, Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors [J]. Oral Dis, 2007, 13(5)∶461-467
[2] Utermark T. The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis [J]. Genes Dev, 2012,26(14)∶1573-86
[3] Aberg, T., J. Wozney, I. Thesleff, Expression patterns of bone morphogenetic proteins (Bmps) in the developing mouse tooth suggest roles in morphogenesis and cell differentiation [J]. Dev Dyn, 1997, 210(4)∶383-96
[4] Assaraf-Weill N. Ameloblasts express type I collagen during amelogenesis [J]. J Dent Res, 2014, 93(5)∶502-7
[5] Tucker, A. P. Sharpe, The cutting-edge of mammalian development; how the embryo makes teeth [J]. Nat Rev Genet, 2004, 5(7)∶499-508
[6] Brook AH. Multilevel complex interactions between genetic, epigenetic and environmental factors in the aetiology of anomalies of dental development [J]. Arch Oral Biol, 2009, 54(1)∶S3-17
[7] Li J. BMP-SHH signaling network controls epithelial stem cell fate via regulation of its niche in the developing tooth [J]. Dev Cell, 2015, 33(2)∶125-35
[8] 梁鑫, 王.成纤维细胞生长因子及其受体在牙齿生长发育中的作用[J].口腔医学研究,2016,32(4)∶421-423
[9] Leevers, S.J., B. Vanhaesebroeck, M.D. Waterfield, Signalling through phosphoinositide 3-kinases: the lipids take centre stage [J]. Curr Opin Cell Biol, 1999, 11(2)∶219-225
[10] Carpenter CL. Purification and characterization of phosphoinositide 3-kinase from rat liver [J]. J Biol Chem, 1990, 265(32)∶19704-19711
[11] Papa A. Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function [J]. Cell, 2014, 157(3)∶595-610
[12] Newton AC. L.C. Trotman, Turning off AKT: PHLPP as a drug target [J]. Annu Rev Pharmacol Toxicol, 2014, 54(5)∶537-558
[13] Nakao, Y. Fibroblast growth factors 7 and 10 are involved in ameloblastoma proliferation via the mitogen-activated protein kinase pathway. Int J Oncol, 2013, 43(5)∶1377-1384
[14] Li N. Expression of phosphorylated Akt/mTOR and clinical significance in human ameloblastoma [J]. Int J Clin Exp Med, 2015, 8(4)∶5236-5244
[15] Scheper MA. Expression and alterations of the PTEN / AKT / mTOR pathway in ameloblastomas [J]. Oral Dis, 2008, 14(6)∶561-568
[16] Kaye FJ. Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma [J]. J Natl Cancer Inst, 2015, 107(1)∶378-383 |